| Literature DB >> 31926020 |
Oana Sorop1, Jens van de Wouw1, Selena Chandler2, Vahagn Ohanyan2, Johnathan D Tune3, William M Chilian2, Daphne Merkus1,4,5, Shawn B Bender6,7,8, Dirk J Duncker1.
Abstract
Coronary microvascular dysfunction (CMD) is commonly present in patients with metabolic derangements and is increasingly recognized as an important contributor to myocardial ischaemia, both in the presence and absence of epicardial coronary atherosclerosis. The latter condition is termed 'ischaemia and no obstructive coronary artery disease' (INOCA). Notwithstanding the high prevalence of INOCA, effective treatment remains elusive. Although to date there is no animal model for INOCA, animal models of CMD, one of the hallmarks of INOCA, offer excellent test models for enhancing our understanding of the pathophysiology of CMD and for investigating novel therapies. This article presents an overview of currently available experimental models of CMD-with an emphasis on metabolic derangements as risk factors-in dogs, swine, rabbits, rats, and mice. In all available animal models, metabolic derangements are most often induced by a high-fat diet (HFD) and/or diabetes mellitus via injection of alloxan or streptozotocin, but there is also a wide variety of spontaneous as well as transgenic animal models which develop metabolic derangements. Depending on the number, severity, and duration of exposure to risk factors-all these animal models show perturbations in coronary microvascular (endothelial) function and structure, similar to what has been observed in patients with INOCA and comorbid conditions. The use of these animal models will be instrumental in identifying novel therapeutic targets and for the subsequent development and testing of novel therapeutic interventions to combat ischaemic heart disease, the number one cause of death worldwide.Entities:
Keywords: Animal model; Coronary microvascular dysfunction; Endothelial dysfunction; INOCA; Metabolic derangements
Year: 2020 PMID: 31926020 PMCID: PMC7061277 DOI: 10.1093/cvr/cvaa002
Source DB: PubMed Journal: Cardiovasc Res ISSN: 0008-6363 Impact factor: 10.787
Main mechanisms involved in CMD per animal model
| Functional | Structural | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Endothelium-dependent | Neurohumoral | VSMC | Arteriolar | Capillary | |||||
| ↓NO | ↑ROS | ↑ET-1 | ↓PGI2 | ↑RAAS | ↑SNS | ↓function | ↑ Media thickness | ↓Density | |
| Canine models | |||||||||
| Alloxan | + | NA | NA | NA | NA | + | + | NA | NA |
| High-fat diet | NA | NA | − | NA | + | + | − | NA | NA |
| Adipokine infusion | ∼ | − | NA | − | NA | NA | − | NA | NA |
| Porcine models | |||||||||
| Induced domestic | + | + | ∼ | NA | NA | NA | ∼ | NA | + |
| Induced Yucatan | ∼ | NA | NA | − | NA | NA | + | NA | NA |
| Rapacz FH | + | NA | NA | NA | NA | NA | − | NA | NA |
| Ossabaw | ∼ | NA | NA | NA | NA | NA | ∼ | NA | + |
| Rabbit models | |||||||||
| Alloxan | + | NA | NA | + | NA | NA | − | NA | NA |
| High-fat diet | ∼ | + | + | NA | NA | + | ∼ | + | NA |
| WHHL | NA | NA | NA | NA | NA | NA | − | NA | NA |
| Rat models | |||||||||
| Streptozotocin | ∼ | − | NA | − | + | NA | ∼ | ∼ | ∼ |
| High-fat diet | + | NA | NA | NA | + | NA | ∼ | NA | − |
| Zucker | ∼ | + | − | ∼ | NA | ∼ | − | − | NA |
| OLETF | ∼ | + | + | NA | + | NA | − | + | NA |
| GK | ∼ | NA | NA | − | NA | + | + | + | − |
| Murine models | |||||||||
| db/db | + | + | NA | NA | + | NA | ∼ | ∼ | ∼ |
| ob/ob | + | NA | NA | NA | NA | NA | − | NA | − |
| Induced T1 + 2DM | + | + | + | NA | NA | + | + | + | NA |
| apoE | + | + | NA | − | NA | NA | − | NA | NA |
Overview of models of coronary microvascular dysfunction per species and what features are present (+), absent (−), ambiguous results (∼), or not investigated (NA; not assessed).
apoE, apolipoprotein E knockout mouse; db/db, leptin receptor deficient mouse; ET-1, endothelin 1; FH, familial hypercholesterolaemia; GK, Goto-Kakizaki non-obese diabetic rat; NO, nitric oxide; ob/ob, leptin deficient mouse; OLETF, Otsuka Long-Evans Tokushima Fatty rat; PGI2, prostacyclin; RAAS, renin–angiotensin aldosterone system; ROS, reactive oxygen species; SNS, sympathetic nervous system; T1 + 2DM, type 1 and 2 diabetes mellitus; VSMC, vascular smooth muscle cell; WHHL, Watanabe heritable hyperlipidaemic rabbit; Zucker, Zucker obese and diabetic fatty rats.